Nkarta to Participate in an April Investor Conference
Tuesday, April 1, 2025 1 min read
Key Takeaway: Nkarta, Inc. has announced its participation in an upcoming investor conference, which will be accessible via a webcast. The company focuses on developing engineered NK cell therapies for autoimmune diseases, utilizing advanced technologies like CRISPR. A replay of the event will be available on their website for 90 days.
Price reaction · baseline $1.84 (2025-03-31 close) · hit pre-market · clean, no other NKTX news in the window
day 0 close
+0.3%
Market Sentiment Analysis
POSITIVE FACTORS
Nkarta is actively participating in investor conferences, indicating engagement with stakeholders.
The company is advancing innovative NK cell therapies for autoimmune diseases.
Nkarta's use of CRISPR-based technologies showcases its commitment to cutting-edge research.
Full Press Release Details
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
24th Annual Needham Virtual Healthcare Conference
April 8, 2025
11:00 a.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website,www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website atwww.nkartatx.com.